Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks

AK Keita, FR Koundouno, M Faye, A Düx, J Hinzmann… - Nature, 2021 - nature.com
Seven years after the declaration of the first epidemic of Ebola virus disease in Guinea, the
country faced a new outbreak—between 14 February and 19 June 2021—near the …

Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study

JF Etard, MS Sow, S Leroy, A Touré… - The Lancet Infectious …, 2017 - thelancet.com
Background The high number of survivors from the 2013–16 west African outbreak of Ebola
virus disease (EVD) has raised several new issues: long-term clinical complications …

Ebola outbreak in Conakry, Guinea: epidemiological, clinical, and outcome features

M Barry, FA Traoré, FB Sako, DO Kpamy, EI Bah… - Medecine et maladies …, 2014 - Elsevier
Objectives The authors studied the epidemiological, clinical, and outcome features of the
Ebola virus disease in patients hospitalized at the Ebola treatment center (ETC) in Conakry …

Interferon β-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial

MK Konde, DP Baker, FA Traore, MS Sow, A Camara… - PloS one, 2017 - journals.plos.org
To date there are no approved antiviral drugs for the treatment of Ebola virus disease (EVD).
Based on our in vitro evidence of antiviral activity of interferon (IFN)-ß activity against Ebola …

[HTML][HTML] Clinical presentation, outcomes and factors associated with mortality: A prospective study from three COVID-19 referral care centres in West Africa

M Jaspard, MS Sow, S Juchet, E Diendere… - International Journal of …, 2021 - Elsevier
Objectives The overall death toll from COVID-19 in Africa is reported to be low but there is
little individual-level evidence on the severity of the disease. This study examined the …

Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea: a 60-month observational prospective cohort study

MSK Diallo, A Ayouba, G Thaurignac, MS Sow… - The Lancet …, 2021 - thelancet.com
Background Insufficient long-term data are available on antibody kinetics in survivors of
Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have …

Facilitators and barriers to COVID-19 vaccination among healthcare workers and the general population in Guinea

AA Toure, FA Traore, G Camara, AS Magassouba… - BMC Infectious …, 2022 - Springer
Introduction The advent of the effective COVID-19 vaccine was the most eagerly expected
worldwide. However, this hope quickly became hesitation and denial in many countries …

Clinical predictors of mortality in patients with Ebola virus disease

M Barry, A Touré, FA Traoré, FB Sako… - Clinical infectious …, 2015 - academic.oup.com
In an observational cohort study including 89 Ebola patients, predictive factors of death were
analyzed. The crude mortality rate was 43.8%. Myalgia (adjusted odds ratio [OR], 4.04; P …

Investing in preparedness for rapid detection and control of epidemics: analysis of health system reforms and their effect on 2021 Ebola virus disease epidemic …

M Keita, A Talisuna, D Chamla, B Burmen… - BMJ Global …, 2023 - gh.bmj.com
The 2014–2016 West Africa Ebola Virus Disease (EVD) Epidemic devastated Guinea's
health system and constituted a public health emergency of international concern. Following …

Extraordinary long-term and fluctuating persistence of Ebola virus RNA in semen of survivors in Guinea: implications for public health

AK Keita, A Toure, MS Sow… - Clinical …, 2017 - clinicalmicrobiologyandinfection …
The 2013e2016 West African Ebola virus outbreak, with 28 616 cases and 11 310 deaths
reported as of 11 May 2016, has been of international public health concern [1]. Seventy …